Antibodies used in the study
Antibody . | Clone . | Source . | Dilution . |
|---|---|---|---|
| Bcl-2 | 124 | DAKO | 1:20 |
| Bcl-XL | 2H12 | ZYMED | 1:50 |
| Bcl-6 | PG-B6p | DAKO | 1:10 |
| CD3 | — | Cell Marque/Novocastra | 1:100 |
| CD4 | 4B12 | Novocastra | 1:50 |
| CD7 | CD7-272 | Novocastra | 1:30 |
| CD8 | C8/144B | DAKO | 1:50 |
| CD10 | 56C6 | Novocastra | 1:50 |
| CD20 | L26 | DAKO | 1:500 |
| Ki67 | MIB1 | DAKO | 1:100 |
| CD21 | 1F8 | DAKO | 1:30 |
| CD57 | NK-1 | Novocastra | 1:30 |
| CD68 | KP1 | DAKO | 1:2000 |
| TIA-1 | 2G9A10F5 | Beckman | 1:250 |
Antibody . | Clone . | Source . | Dilution . |
|---|---|---|---|
| Bcl-2 | 124 | DAKO | 1:20 |
| Bcl-XL | 2H12 | ZYMED | 1:50 |
| Bcl-6 | PG-B6p | DAKO | 1:10 |
| CD3 | — | Cell Marque/Novocastra | 1:100 |
| CD4 | 4B12 | Novocastra | 1:50 |
| CD7 | CD7-272 | Novocastra | 1:30 |
| CD8 | C8/144B | DAKO | 1:50 |
| CD10 | 56C6 | Novocastra | 1:50 |
| CD20 | L26 | DAKO | 1:500 |
| Ki67 | MIB1 | DAKO | 1:100 |
| CD21 | 1F8 | DAKO | 1:30 |
| CD57 | NK-1 | Novocastra | 1:30 |
| CD68 | KP1 | DAKO | 1:2000 |
| TIA-1 | 2G9A10F5 | Beckman | 1:250 |
ZYMED (Invitrogen, Carlsbad, CA); Cell Marque (Hot Springs, AR); Novocastra (Newcastle upon Tyne, United Kingdom).
— indicates CD3 clone PS1 (Ultra Marque CD3).